Wedbush Maintains Outperform on Stericycle

Wedbush is out with its report today on Stericycle

, maintaining Outperform. In a note to clients, Wedbush writes, "With upside potential in FY11 guidance related to M&A, operational synergies, and increased activity in the RMS business, we are maintaining our OUTPERFORM rating and favorable stance on SRCL's risk-reward profile at current valuations." Wedbush maintains a $100 PT on SRCL. Shares of SRCL closed Monday at $89.80.